Als Nachtrag zu dem vorgestellten Wert GME noch folgendes:
Auf meine Frage an die Gesellschaft, wieviel Mittel das Joint-
Venture mit Eyedentity schon verschlungen hat (um zu sehen, wie
stark sich die Gesellschaft finanziell an den Forschungen beteiligen
muß), bekam ich folgende Antwort:

Our 10-Q was filed with the SEC last Friday and in it you will notice that
as of Januar 16, 1999, Diacrin had contributed 3.6M to the joint venture
and Genzyme had contributed 20.7 M.  We expect by the end of this year
approximately 27M will have been contributed to the joint venture.  We
expect that the joint venture will remain in its current funding status
(75% Genzyme/ 25% Diacrin) through at least mid-2001.  Of course it's
impossible in the biotech industry to determine future spending with
accuracy as it is dependent on ongoing clinical progress.

Thank you for your interest in GME, Inc.


Gruß Victor